Cocco and collaborators found that potentially targetable fusions of oncogenes such as NTRK, BRAF, RET, FGFR, ROS1 and ALK were present in 5% of dMMR/MSI-H CRC as compared to only 0.4% of MSS CRC cases. This evidence concerns the gene ROS1 and colorectal carcinoma.